PESG Research, a research group under the Future Markets Research Tank (FMRT), is proud to release market commentary on Innocan Pharma, an up-and-coming leader in the CBD veterinary solutions Industry. To read the full report click here, or follow the link: https://bit.ly/3iFtXnN Key Insights: It’s apparent that the veterinary pharma industry offers substantial economic opportunities for the nimble competitor. Given the attractive attributes of its emerging drug technologies, Innocan is poised to take a leadership role in this nascent sector. Innocan has developed several new drug delivery platforms to tackle the perceived low bioavailability of CBD head-on and significantly improve upon current delivery mechanisms. Both of Innocan’s LPT and CSX technologies have commercially feasible applications in the veterinary services realm to combat maladies like anxiety, inflammation, and pain management. CBD as a medical solution for animals is still in its infancy. Although many substantial Pharma companies are active in Veterinary Services, Innocan stands alone in targeting the intersection of Veterinary Services and CBD. As Innocan moves to begin the licensing and monetization of its technology, the company will likely become a viable acquisition target for deep-pocked competitors. Recent transactions highlight market interest in cannabis and differentiated
Cannabis Law Report, 03/28/2022 14:42:00